Perfromance Wealth Partners’s Quest Diagnostics DGX Stock Holding History

Perfromance Wealth Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,268	Closed	-$1.69M	–	172
2023 Q4	$1.69M	Sell	12,268 -6,667	-35%	-$877K	0.07%	61
2023 Q3	$2.31M	Sell	18,935 -2,157	-10%	-$287K	0.11%	57
2023 Q2	$2.91M	Sell	21,092 -2,646	-11%	-$365K	0.13%	54
2023 Q1	$3.36M	Sell	23,738 -1,895	-7%	-$271K	0.17%	44
2022 Q4	$4.01M	Sell	25,633 -2,143	-8%	-$308K	0.24%	34
2022 Q3	$3.41M	Sell	27,776 -1,391	-5%	-$183K	0.2%	35
2022 Q2	$3.88M	Sell	29,167 -756	-3%	-$103K	0.22%	36
2022 Q1	$4.09M	Sell	29,923 -674	-2%	-$93.9K	0.18%	41
2021 Q4	$5.29M	Buy	+30,597	New	+$4.66M	0.21%	42

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Perfromance Wealth Partners's DGX Position: Q1 2024 in Review

Perfromance Wealth Partners sold out of Quest Diagnostics (DGX) in Q1 2024, closing a stake of 12,268 shares — an estimated $1.69M sold.

Perfromance Wealth Partners first reported a position in DGX in Q4 2021 and held it in 9 quarters. The position peaked at $5.29M in Q4 2021. 819 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

Perfromance Wealth Partners reported no remaining Quest Diagnostics position as of Q1 2024 after selling out during the quarter.
Perfromance Wealth Partners sold 12,268 Quest Diagnostics shares in Q1 2024, an estimated $1.69M.
Perfromance Wealth Partners first reported a position in Quest Diagnostics in Q4 2021 and held it in 9 quarters.
Perfromance Wealth Partners's Quest Diagnostics position peaked at $5.29M in Q4 2021.
819 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Perfromance Wealth Partners's 13F filing for Q1 2024, filed 30 Apr 2024.